CDH1 and breast cancer: Finally, assays to detect and characterize large rearrangements in the intron 2 of the CDH1 gene are evolving and molecular exploration will be needed to understand the etiology of the other 145 BC cases with no BRCA1/2 and CDH1 pathogenic variants with the third generation sequencing NGS [35] and the target-enriched Nanopore sequencing [27,36].